High VLDL causes: Difference between revisions
Jump to navigation
Jump to search
No edit summary |
Rim Halaby (talk | contribs) |
||
(15 intermediate revisions by 2 users not shown) | |||
Line 1: | Line 1: | ||
__NOTOC__ | __NOTOC__ | ||
{{VLDL}} | {{VLDL}} | ||
{{CMG}} | {{CMG}}; {{AE}} {{M.P}} | ||
==Overview== | ==Overview== | ||
High VLDL may be a consequence of [[inherited]] diseases that affect the [[lipid metabolism]], or cab be due to secondary causes such as drugs and [[chronic liver disease]]. | |||
==Causes== | ==Causes== | ||
Line 12: | Line 12: | ||
===Common Causes=== | ===Common Causes=== | ||
*[[Chronic liver disease]] | *[[Chronic liver disease]] | ||
*[[Corticosteroids]] | |||
*[[diabetes mellitus|Diabetes mellitus type 2]] | |||
*[[Familial hypercholesterolemia]]<ref name="Durrington-2003">{{Cite journal | last1 = Durrington | first1 = P. | title = Dyslipidaemia. | journal = Lancet | volume = 362 | issue = 9385 | pages = 717-31 | month = Aug | year = 2003 | doi = 10.1016/S0140-6736(03)14234-1 | PMID = 12957096 }}</ref> | *[[Familial hypercholesterolemia]]<ref name="Durrington-2003">{{Cite journal | last1 = Durrington | first1 = P. | title = Dyslipidaemia. | journal = Lancet | volume = 362 | issue = 9385 | pages = 717-31 | month = Aug | year = 2003 | doi = 10.1016/S0140-6736(03)14234-1 | PMID = 12957096 }}</ref> | ||
*[[Saturated fat|High saturated fat diet]]<ref name="Covington-2004">{{Cite journal | last1 = Covington | first1 = MB. | title = Omega-3 fatty acids. | journal = Am Fam Physician | volume = 70 | issue = 1 | pages = 133-40 | month = Jul | year = 2004 | doi = | PMID = 15259529 }}</ref> | *[[Saturated fat|High saturated fat diet]]<ref name="Covington-2004">{{Cite journal | last1 = Covington | first1 = MB. | title = Omega-3 fatty acids. | journal = Am Fam Physician | volume = 70 | issue = 1 | pages = 133-40 | month = Jul | year = 2004 | doi = | PMID = 15259529 }}</ref> | ||
*[[ | *[[Hepatitis]] | ||
===Causes by Organ System=== | ===Causes by Organ System=== | ||
Line 37: | Line 38: | ||
|-bgcolor="LightSteelBlue" | |-bgcolor="LightSteelBlue" | ||
| '''Drug Side Effect''' | | '''Drug Side Effect''' | ||
|bgcolor="Beige"| [[ | |bgcolor="Beige"| [[Azathioprine]], [[bexarotene]], [[Immunosuppressive drug#Drugs acting on immunophilins|calcineurin inhibitors]], [[chlortalidone]], [[corticosteroids]], [[cyclosporine]], [[desvenlafaxine]], [[immunosuppressive agents]], [[levonorgestrel]], [[lopinavir]], [[mycophenolate]], [[nicotine]], [[norgestrel]], [[prednisone]], [[progestin]], [[protease inhibitors]], [[rapamycin]], [[rosiglitazone]], [[sirolimus]], [[thiazide]], [[tocilizumab]] | ||
|- | |- | ||
|-bgcolor="LightSteelBlue" | |-bgcolor="LightSteelBlue" | ||
Line 45: | Line 46: | ||
|-bgcolor="LightSteelBlue" | |-bgcolor="LightSteelBlue" | ||
| '''Endocrine''' | | '''Endocrine''' | ||
|bgcolor="Beige"| [[ | |bgcolor="Beige"| [[Acromegaly]], [[Cushing's syndrome]], [[dehydroepiandrosterone]], [[diabetes mellitus type 2]], [[hypercortisolism]], [[hypothyroidism]], [[polycystic ovarian syndrome]], [[Hypothyroidism|subclinical hypothyroidism]] | ||
|- | |- | ||
|-bgcolor="LightSteelBlue" | |-bgcolor="LightSteelBlue" | ||
Line 53: | Line 54: | ||
|-bgcolor="LightSteelBlue" | |-bgcolor="LightSteelBlue" | ||
| '''Gastroenterologic''' | | '''Gastroenterologic''' | ||
|bgcolor="Beige"| | |bgcolor="Beige"| [[Acute hepatitis]], [[chronic liver disease]], [[obstructive jaundice]] | ||
|- | |- | ||
|-bgcolor="LightSteelBlue" | |-bgcolor="LightSteelBlue" | ||
| '''Genetic''' | | '''Genetic''' | ||
|bgcolor="Beige"| [[Niemann-Pick disease|Acid sphingomyelinase deficiency]], [[Familial hypercholesterolemia|autosomal recessive hypercholesterolemia]], [[familial combined hyperlipidemia]], [[Apolipoprotein B deficiency|familial defective apolipoprotein B-100]], [[familial hypercholesterolemia]], [[familial hypertriglyceridaemia]], [[familial mixed hyperlipidaemia]], [[Interleukin 28#Clinical Significance|IL 28B polymorphisms]], [[Niemann-Pick disease]], [[hypercholesterolemia|polygenic hypercholesterolemia]] | |bgcolor="Beige"| [[Niemann-Pick disease|Acid sphingomyelinase deficiency]], [[apolipoprotein C2|apolipoprotein C-II deficiency]], [[Familial hypercholesterolemia|autosomal recessive hypercholesterolemia]], [[familial combined hyperlipidemia]], [[Apolipoprotein B deficiency|familial defective apolipoprotein B-100]], [[familial hypercholesterolemia]], [[Hyperlipoproteinemia|familial hyperlipoproteinemia type 5]], [[familial hypertriglyceridaemia]], [[familial mixed hyperlipidaemia]], [[Interleukin 28#Clinical Significance|IL 28B polymorphisms]], [[lipoprotein lipase deficiency]], [[Niemann-Pick disease]], [[hypercholesterolemia|polygenic hypercholesterolemia]] | ||
|- | |- | ||
|-bgcolor="LightSteelBlue" | |-bgcolor="LightSteelBlue" | ||
Line 69: | Line 70: | ||
|-bgcolor="LightSteelBlue" | |-bgcolor="LightSteelBlue" | ||
| '''Infectious Disease''' | | '''Infectious Disease''' | ||
|bgcolor="Beige"| [[Gram negative bacteremia]], | |bgcolor="Beige"| [[Gram negative bacteremia|Gram negative sepsis]], [[H. pylori|H. pylori infection]], [[small bowel bacterial overgrowth syndrome]] | ||
|- | |- | ||
|-bgcolor="LightSteelBlue" | |-bgcolor="LightSteelBlue" | ||
Line 81: | Line 82: | ||
|-bgcolor="LightSteelBlue" | |-bgcolor="LightSteelBlue" | ||
| '''Nutritional/Metabolic''' | | '''Nutritional/Metabolic''' | ||
|bgcolor="Beige"| [[Chenodeoxycholic acid]], | |bgcolor="Beige"| [[Chenodeoxycholic acid]], [[Carbohydrate#Nutrition|high carbohydrate diet]], [[Saturated fat|high saturated fat diet]], [[Hypercholesterolemia|polygenic hypercholesterolemia]], [[primary hyperlipoproteinemia]], [[Hypolipoproteinemia pathophysiology#Primary Lipoprotein Disorders|primary hypolipoproteinemia]], [[selenium deficiency]] | ||
|- | |- | ||
|-bgcolor="LightSteelBlue" | |-bgcolor="LightSteelBlue" | ||
Line 89: | Line 90: | ||
|-bgcolor="LightSteelBlue" | |-bgcolor="LightSteelBlue" | ||
| '''Oncologic''' | | '''Oncologic''' | ||
|bgcolor="Beige"| | |bgcolor="Beige"| [[Lymphoma]], [[multiple myeloma]] | ||
|- | |- | ||
|-bgcolor="LightSteelBlue" | |-bgcolor="LightSteelBlue" | ||
Line 109: | Line 110: | ||
|-bgcolor="LightSteelBlue" | |-bgcolor="LightSteelBlue" | ||
| '''Renal/Electrolyte''' | | '''Renal/Electrolyte''' | ||
|bgcolor="Beige"| [[Chronic kidney disease]], | |bgcolor="Beige"| [[Chronic kidney disease]], [[nephrotic syndrome]], [[uremia]] | ||
|- | |- | ||
|-bgcolor="LightSteelBlue" | |-bgcolor="LightSteelBlue" | ||
| '''Rheumatology/Immunology/Allergy''' | | '''Rheumatology/Immunology/Allergy''' | ||
|bgcolor="Beige"| [[Dysproteinemia]], | |bgcolor="Beige"| [[Dysproteinemia]], [[monoclonal gammopathy]], [[multiple myeloma]], [[paraproteinemia]] | ||
|- | |- | ||
|-bgcolor="LightSteelBlue" | |-bgcolor="LightSteelBlue" | ||
Line 129: | Line 130: | ||
|-bgcolor="LightSteelBlue" | |-bgcolor="LightSteelBlue" | ||
| '''Miscellaneous''' | | '''Miscellaneous''' | ||
|bgcolor="Beige"| | |bgcolor="Beige"| [[Alcoholism]] | ||
|- | |- | ||
|} | |} | ||
Line 137: | Line 138: | ||
{{col-break|width=33%}} | {{col-break|width=33%}} | ||
*[[Niemann-Pick disease|Acid sphingomyelinase deficiency]] | *[[Niemann-Pick disease|Acid sphingomyelinase deficiency]] | ||
*[[ | *[[Acromegaly]] | ||
*[[ | *[[Acute hepatitis]] | ||
*[[Alcoholism]] | |||
*[[apolipoprotein C2|Apolipoprotein C-II deficiency]] | |||
*[[Familial hypercholesterolemia|Autosomal recessive hypercholesterolemia]] | *[[Familial hypercholesterolemia|Autosomal recessive hypercholesterolemia]] | ||
*[[Azathioprine]] | *[[Azathioprine]] | ||
*[[Bexarotene]] | *[[Bexarotene]] | ||
*[[Immunosuppressive drug#Drugs acting on immunophilins|Calcineurin inhibitors]] | *[[Immunosuppressive drug#Drugs acting on immunophilins|Calcineurin inhibitors]] | ||
*[[Chlortalidone]] | *[[Chlortalidone]] | ||
*[[Chronic kidney disease]] | *[[Chronic kidney disease]] | ||
*[[Chronic liver disease]] | *[[Chronic liver disease]] | ||
*[[Corticosteroids]] | *[[Corticosteroids]] | ||
*[[Cushing's syndrome]] | |||
*[[Cyclosporine]] | *[[Cyclosporine]] | ||
*[[Desvenlafaxine]] | *[[Desvenlafaxine]] | ||
*[[Diabetes mellitus|Diabetes mellitus type 2]] | |||
*[[Terpenoid|Diterpenoids]] | *[[Terpenoid|Diterpenoids]] | ||
*[[Dysproteinemia]] | *[[Dysproteinemia]] | ||
*[[Familial combined hyperlipidemia]] | *[[Familial combined hyperlipidemia]] | ||
{{col-break|width=33%}} | |||
*[[Apolipoprotein B deficiency|Familial defective apolipoprotein B-100]] | *[[Apolipoprotein B deficiency|Familial defective apolipoprotein B-100]] | ||
*[[Familial hypercholesterolemia]]<ref name="Durrington-2003">{{Cite journal | last1 = Durrington | first1 = P. | title = Dyslipidaemia. | journal = Lancet | volume = 362 | issue = 9385 | pages = 717-31 | month = Aug | year = 2003 | doi = 10.1016/S0140-6736(03)14234-1 | PMID = 12957096 }}</ref> | *[[Familial hypercholesterolemia]]<ref name="Durrington-2003">{{Cite journal | last1 = Durrington | first1 = P. | title = Dyslipidaemia. | journal = Lancet | volume = 362 | issue = 9385 | pages = 717-31 | month = Aug | year = 2003 | doi = 10.1016/S0140-6736(03)14234-1 | PMID = 12957096 }}</ref> | ||
*[[Hyperlipoproteinemia|Familial hyperlipoproteinemia type 5]] | |||
*[[ | *[[Familial mixed hyperlipidaemia]] | ||
*[[Gram negative bacteremia]] | *[[Gram negative bacteremia]] | ||
*[[H. pylori]] | *[[H. pylori]] | ||
*[[Carbohydrate#Nutrition|High carbohydrate diet]] | *[[Carbohydrate#Nutrition|High carbohydrate diet]] | ||
Line 168: | Line 170: | ||
*[[Interleukin 28#Clinical Significance|IL 28B polymorphisms]] | *[[Interleukin 28#Clinical Significance|IL 28B polymorphisms]] | ||
*[[Immunosuppressive agents]] | *[[Immunosuppressive agents]] | ||
*[[Levonorgestrel]] | *[[Levonorgestrel]] | ||
*[[ | *[[Lipoprotein lipase deficiency]] | ||
*[[Lopinavir]] | *[[Lopinavir]] | ||
*[[Monoclonal gammopathy]] | *[[Monoclonal gammopathy]] | ||
*[[Multiple myeloma]] | |||
*[[Mycophenolate]] | *[[Mycophenolate]] | ||
*[[Nephrotic syndrome]]<ref name="Kronenberg-2005">{{Cite journal | last1 = Kronenberg | first1 = F. | title = Dyslipidemia and nephrotic syndrome: recent advances. | journal = J Ren Nutr | volume = 15 | issue = 2 | pages = 195-203 | month = Apr | year = 2005 | doi = | PMID = 15827892 }}</ref> | *[[Nephrotic syndrome]]<ref name="Kronenberg-2005">{{Cite journal | last1 = Kronenberg | first1 = F. | title = Dyslipidemia and nephrotic syndrome: recent advances. | journal = J Ren Nutr | volume = 15 | issue = 2 | pages = 195-203 | month = Apr | year = 2005 | doi = | PMID = 15827892 }}</ref> | ||
*[[Nicotine]] | *[[Nicotine]] | ||
{{col-break|width=33%}} | |||
*[[Niemann-Pick disease]] | *[[Niemann-Pick disease]] | ||
*[[Norgestrel]] | *[[Norgestrel]] | ||
*[[Xanthomatous biliary cirrhosis|Obstructive liver disease]] | *[[Xanthomatous biliary cirrhosis|Obstructive liver disease]] | ||
*[[Paraproteinemia]] | *[[Paraproteinemia]] | ||
*[[Polycystic ovarian syndrome]] | *[[Polycystic ovarian syndrome]] | ||
*[[Hypercholesterolemia|Polygenic hypercholesterolemia]] | *[[Hypercholesterolemia|Polygenic hypercholesterolemia]] | ||
*[[Prednisone]] | *[[Prednisone]] | ||
*[[Primary hyperlipoproteinemia]] | *[[Primary hyperlipoproteinemia]] | ||
*[[Hypolipoproteinemia pathophysiology#Primary Lipoprotein Disorders|Primary hypolipoproteinemia]] | *[[Hypolipoproteinemia pathophysiology#Primary Lipoprotein Disorders|Primary hypolipoproteinemia]] | ||
*[[ | *[[Protease inhibitors]] | ||
*[[Rapamycin]] | *[[Rapamycin]] | ||
*[[Rosiglitazone]] | *[[Rosiglitazone]] | ||
Line 200: | Line 198: | ||
*[[Thiazide]] | *[[Thiazide]] | ||
*[[Tocilizumab]] | *[[Tocilizumab]] | ||
*[[Uremia]] | |||
{{col-end}} | {{col-end}} | ||
Latest revision as of 17:37, 20 November 2013
Very Low Density Lipoprotein Microchapters |
Clinical Correlation |
---|
Treatment |
Case Studies |
High VLDL causes On the Web |
American Roentgen Ray Society Images of High VLDL causes |
Directions to Hospitals Treating Very low density lipoprotein |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Mugilan Poongkunran M.B.B.S [2]
Overview
High VLDL may be a consequence of inherited diseases that affect the lipid metabolism, or cab be due to secondary causes such as drugs and chronic liver disease.
Causes
Life Threatening Causes
Life-threatening causes include conditions which may result in death or permanent disability within 24 hours if left untreated.
Common Causes
- Chronic liver disease
- Corticosteroids
- Diabetes mellitus type 2
- Familial hypercholesterolemia[1]
- High saturated fat diet[2]
- Hepatitis
Causes by Organ System
Causes in Alphabetical Order
References
- ↑ 1.0 1.1 Durrington, P. (2003). "Dyslipidaemia". Lancet. 362 (9385): 717–31. doi:10.1016/S0140-6736(03)14234-1. PMID 12957096. Unknown parameter
|month=
ignored (help) - ↑ 2.0 2.1 Covington, MB. (2004). "Omega-3 fatty acids". Am Fam Physician. 70 (1): 133–40. PMID 15259529. Unknown parameter
|month=
ignored (help) - ↑ Kronenberg, F. (2005). "Dyslipidemia and nephrotic syndrome: recent advances". J Ren Nutr. 15 (2): 195–203. PMID 15827892. Unknown parameter
|month=
ignored (help)